ROLFE LINDSEY (See Remarks) sold 2.5% of their position (2.65K shares) of CLOVIS ONCOLOGY, INC. on the open market
Open‑market sale worth $1.7K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/3/2022ACC: 0000899243-22-020946
Officer· See Remarks
Since Sep 2018
+7.47K
Net shares
Net buyer
$1.7K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
10.12K acquired · 2.65K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+5.06K
Price / share
—
Trade value
—
% of position
5.0%
6/1/2022
100.60K→105.67K
Common Stock
Direct
Shares
−2.65K
Price / share
$0.64
Trade value
$1.70K
% of position
2.5%
6/2/2022
105.67K→103.02K
Total
Net shares
+2.41K
Net value
-$1.70K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/1/2022 | M · Option Exercise | +5.06K | — | — | 5.0% | 100.60K | 105.67K |
| Common Stock Direct | 6/2/2022 | S · Sale | −2.65K | $0.64 | $1.70K | 2.5% | 105.67K | 103.02K |
| Total | +2.41K | -$1.70K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Common Stock
5.06K shares
Shares
+5.06K
Strike price
Held after
55.69K
Exercisable
—
6/1/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock5.06K shares | 6/1/2022 | M · Option Exercise | +5.06K | — | 55.69K |